Journal of Antimicrobial Chemotherapy, Vol 42, 217-220, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
KG Davey, EM Johnson, AD Holmes, A Szekely and DW Warnock
The in-vitro susceptibilities of 143 isolates of Cryptococcus neoformans,
collected from British patients between 1994 and 1996, to fluconazole and
itraconazole were compared with those of 36 isolates collected between 1971
and 1985, 41 isolates collected between 1986 and 1989, and 43 Ugandan
isolates collected in 1996. Testing was done with a broth microdilution
method in YNB medium supplemented with glucose, incubation at 30 degrees C
for 72 h, and an endpoint of 50% inhibition. The results showed that the
MIC ranges, MIC50s and MIC90s of fluconazole and itraconazole for C.
neoformans isolates from the UK have remained unchanged despite the recent
widespread use of triazoles for long-term maintenance of patients with
AIDS-associated cryptococcal meningitis. The MIC ranges, MIC50s and MIC90s
of the 43 isolates from untreated Ugandan patients with AIDS were similar
to those of the British isolates. Examination of our records for 1994-96
revealed six cases in which a four-fold or greater rise in the MIC of
fluconazole was associated with relapsed cryptococcal meningitis.
ORIGINAL ARTICLES
In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole
PHLS Mycology Reference Laboratory, Public Health Laboratory, Kingsdown, Bristol, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk Efflux-Mediated Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, H. Bijie, D. Dzierzanowska, N. N. Klimko, V. Letscher-Bru, M. Lisalova, K. Muehlethaler, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing J. Clin. Microbiol., January 1, 2009; 47(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004) J. Clin. Microbiol., May 1, 2005; 43(5): 2163 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sar, D. Monchy, M. Vann, C. Keo, J. L. Sarthou, and Y. Buisson Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002 J. Antimicrob. Chemother., August 1, 2004; 54(2): 563 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Brandt, M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998 Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3065 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Petrou and D. C. Shanson Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media J. Antimicrob. Chemother., November 1, 2000; 46(5): 815 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Lopez-Jodra, J. M. Torres-Rodriguez, R. Mendez-Vasquez, E. Ribas-Forcadell, Y. Morera-Lopez, T. Baro-Tomas, and C. Alia-Aponte In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method J. Antimicrob. Chemother., May 1, 2000; 45(5): 645 - 649. [Abstract] [Full Text] [PDF]
|
|